InsiderPulse
Dashboard

XENE

Xenon Pharmaceuticals Inc.

Health CareRussell 2000

Xenon Pharmaceuticals Inc. insider trading

Xenon Pharmaceuticals Inc. files with the SEC as a Pharmaceutical Preparations company headquartered in Burnaby. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent XENE insider transactions

6 insiders traded XENE on the open market between Mar 09, 2026 and Aug 28, 2026 — 20 sales worth $19M, of which 19 were pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$19M

19 of 20 on a 10b5-1 plan

Net
−$19M
Insiders
6

Open-market purchases (code P) and sales (code S) from Xenon Pharmaceuticals Inc.'s own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 23, 2026. The live dashboard shows new filings the moment they clear.

Every XENE Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

XENE insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 7 insiders traded XENE on the open market: 0 purchases and 33 sales worth $25.1M, 28 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 24 sales ($21.9M), by 5 insiders.

QuarterBoughtSold
Q2 2026—−$133.5K2 sales · all on a plan
Q1 2026—−$19.6M17 sales · all on a plan
Q4 2025—−$2.2M5 sales · all on a plan
Q3 2025——
Q2 2025—−$911 sale
Q1 2025—−$2.2M4 sales · all on a plan
Q4 2024—−$971.9K4 sales
Q3 2024——
Largest sale
−$4M of XENE by Mortimer Ian (President & CEO · Director) on Mar 09, 2026, under a 10b5-1 plan.

Open-market transactions through Jun 30, 2026most recent first

  • Mortimer Ian10b5-1

    President & CEO · Director

    −$403.6K

    Mar 13, 2026

    7,308 sh · $55.23

  • Kenney Christopher John10b5-1

    Chief Medical Officer

    −$77.9K

    Mar 13, 2026

    1,410 sh · $55.23

  • DiFabio Andrea10b5-1

    Chief Legal Officer

    −$74.1K

    Mar 13, 2026

    1,342 sh · $55.23

  • Mortimer Ian10b5-1

    President & CEO · Director

    −$677.4K

    Mar 10, 2026

    11,269 sh · $60.11

  • Kenney Christopher John10b5-1

    Chief Medical Officer

    −$166.6K

    Mar 10, 2026

    2,771 sh · $60.11

  • DiFabio Andrea10b5-1

    Chief Legal Officer

    −$156.7K

    Mar 10, 2026

    2,607 sh · $60.11

  • Mortimer Ian10b5-1

    President & CEO · Director

    −$1.7M

    Jan 02, 2026

    37,938 sh · $44.40

  • Mortimer Ian10b5-1

    President & CEO · Director

    −$92.6K

    Jan 02, 2026

    2,062 sh · $44.93

  • Mortimer Ian10b5-1

    President & CEO · Director

    −$402.1K

    Dec 08, 2025

    8,820 sh · $45.59

  • Mortimer Ian10b5-1

    President & CEO · Director

    −$93.1K

    Dec 08, 2025

    2,010 sh · $46.32

  • Mortimer Ian10b5-1

    President & CEO · Director

    −$647.3K

    Dec 05, 2025

    14,375 sh · $45.03

  • Mortimer Ian10b5-1

    President & CEO · Director

    −$4.4K

    Nov 28, 2025

    97 sh · $45.01

  • Mortimer Ian10b5-1

    President, CEO & Interim CFO · Director

    −$1M

    Oct 01, 2025

    25,000 sh · $40.16

  • Gannon Steven

    Director

    −$91

    Jun 05, 2025

    3 sh · $30.48

  • Mortimer Ian10b5-1

    President & CEO · Director

    −$613.6K

    Jan 27, 2025

    15,166 sh · $40.46

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Xenon Pharmaceuticals Inc. company record

SEC industry classification
Pharmaceutical Preparations
Headquarters
Burnaby
Incorporated in
A1
Listed on
Nasdaq
SEC Central Index Key
0001582313

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought XENE

What the stock actually did in the 90 days following each open-market purchase

Don't check XENE — let it ping you

Get told the moment an insider moves on XENE

Pro watches Xenon Pharmaceuticals Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add XENE to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track XENE on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read XENE insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

ZLABATTODNTHUTHRCORTHRMYSUPNOMCLHQYDOCSOSCRALHC
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are XENE insiders buying or selling?
Between Mar 09, 2026 and Aug 28, 2026, 6 Xenon Pharmaceuticals Inc. insiders made no open-market purchases and 20 sales worth $19M, a net sale of $19M. 19 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much XENE stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 7 Xenon Pharmaceuticals Inc. insiders made no open-market purchases and 33 sales worth $25.1M. 28 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 24 sales ($21.9M). The largest sale was Mortimer Ian selling $4M on Mar 09, 2026.
What was the largest recent XENE insider trade?
Mortimer Ian (President & CEO · Director) sold $4M of XENE stock on Mar 09, 2026 at about $62.06 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy XENE shares?
No open-market purchase by a Xenon Pharmaceuticals Inc. insider appears in the filings from Mar 09, 2026 to Aug 28, 2026 — every recorded open-market transaction in that period was a sale.
Where does XENE insider trading data come from?
From the Form 4 filings Xenon Pharmaceuticals Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.